血管生成抑制剂对新诊断原发性多形性胶质母细胞瘤总生存期和无进展生存期的影响:十二项随机临床试验的荟萃分析
该荟萃分析纳入12项随机临床试验共3309例新诊断胶质母细胞瘤患者,评估血管生成抑制剂联合放化疗对比单纯放化疗的疗效。结果显示血管生成抑制剂显著延长无进展生存期(HR 0.85,95%CI 0.73-0.99,P=0.04),但总生存期无显著差异(HR 1.014,95%CI 0.89-1.15,P=0.84)。贝伐珠单抗对无进展生存期改善最大(HR 0.67,95%CI 0.56-0.79,P<0.0001),沙利度胺改善最低(HR 1.46,95%CI 1.004-2.1,P=0.048)。
要点
- 血管生成抑制剂显著延长新诊断胶质母细胞瘤患者无进展生存期(HR 0.85,95%CI 0.73-0.99,P=0.04)。
- 总生存期无显著差异(HR 1.014,95%CI 0.89-1.15,P=0.84)。
- 贝伐珠单抗对无进展生存期改善最大(HR 0.67,95%CI 0.56-0.79,P<0.0001)。
核心结论
- 血管生成抑制剂联合放化疗可改善新诊断胶质母细胞瘤患者的无进展生存期,但对总生存期无显著影响。
- 研究结果可能为成人新诊断胶质母细胞瘤患者使用血管生成抑制剂的决策提供一定证据。
研究设计与样本
- 荟萃分析,检索PubMed/MEDLINE、Scopus、Cochrane和Web of Science数据库,纳入12项随机临床试验共3309例新诊断胶质母细胞瘤患者,采用随机效应模型进行荟萃分析。
主要发现
- 血管生成抑制剂显著延长无进展生存期(HR 0.85,95%CI 0.73-0.99,P=0.04)。
- 总生存期无显著差异(HR 1.014,95%CI 0.89-1.15,P=0.84)。
- 贝伐珠单抗对无进展生存期改善最大(HR 0.67,95%CI 0.56-0.79,P<0.0001)。
- 沙利度胺对无进展生存期改善最低(HR 1.46,95%CI 1.004-2.1,P=0.048)。
- 荟萃回归显示年龄、白人种族、研究样本量、感染、血管疾病并发症、KPS>60、活检、大体和次全切除可显著影响无进展生存期,仅发表年份影响总生存期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Typically treated with initial surgical resection, and chemoradiotherapy, despite current treatments, patients typically survive only 12-14 months, necessitating new therapeutic approaches. Our meta-analysis evaluates combining antiangiogenic medications with chemoradiotherapy versus using chemoradiotherapy alone in treating newly diagnosed GBM. METHODS: A comprehensive literature search was conducted using PubMed/MEDLINE, Scopus, Cochrane and the Web of Science databases. The search aimed to identify studies reporting overall survival (OS), progression-free survival (PFS), and hazard ratio (HR) with corresponding confidence intervals (CIs) in patients with newly diagnosed GBM. We employed random-effect meta-analysis. RESULTS: Twelve randomized clinical trials (RCTs) involved 3,309 patients included in the study. The findings showed that angiogenesis inhibitors significantly prolonged PFS [HR 0.85, 95% CI (0.73, 0.99), p-value = 0.04], while there was no significant difference on OS [HR 1.014, 95%CI (0.89, 1.15), p-value = 0.84]. Bevacizumab (BEV) exhibited the highest [HR 0.67, 95% CI (0.56, 0.79), p-value < 0.0001] and thalidomide exhibited the lowest [HR 1.46, 95% CI (1.004, 2.1), p-value = 0.048] improvements of PFS. Meta-regression revealed that age, white race, study sample size, infection, vascular disease complications, KPS > 60, biopsy, gross and subtotal resection can significantly influenced the PFS, while only the year of publication affected OS. CONCLUSIONS: The current study showed that improve the PFS with no significant effect on OS. Our findings may provide some evidence for decision-making regarding the utilization of angiogenesis inhibitors for the treatment of adult patients with newly diagnosed GBM.
引用
- Motamed-Sanaye A, Mortezaei A, Afshari AR, et al. Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials. J Neurooncol. 2024. PMID: 39636552. doi:10.1007/s11060-024-04865-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。